Trial Profile
A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Tolerability of MK0736 When Added to Ongoing Therapy With Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) in Patients With T2DM and Hypertension
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs MK 0736 (Primary) ; Hydrochlorothiazide
- Indications Hypertension
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 15 Jun 2010 Actual patient number (602) added as reported by ClinicalTrials.gov.
- 15 Jun 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 27 May 2010 Planned end date changed from 1 May 2010 to 1 Jun 2010 as reported by ClinicalTrials.gov record.